Muc18 targeting peptides
AssigneeBoard of Regents, The University of Texas System
InventorsFernanda STAQUICINI, Renata PASQUALINI, Wadih ARAP
Life of this patent
Estimating the term…
Abstract
Provided are MUC18 targeting peptides which may be used, e.g., to therapeutically target B-1 lymphocytes to reduce the influence of these cells on the metastatic potential of melanoma cells and/or to target cancerous cells, including certain melanoma and leukemia cells. MUC18 targeting peptides may be comprised in fusion constructs, imaging constructs, and/or therapeutic constructs such as fusion constructs which may be used for diagnosing or treating a cancer.
Claims20
An isolated peptide that selectively binds melanoma cell adhesion molecule (MUC18), wherein the isolated peptide comprises LFMRLAW (SEQ ID NO:22) or SEQ ID NO:2;
- and wherein if the peptide comprises SEQ ID NO:2, then the peptide is not MUC18.
A nucleic acid that encodes a protein or peptide comprising SEQ ID NO:22, SEQ ID NO:1 or SEQ ID NO:2, wherein if the nucleic acid comprises SEQ ID NO:2, then the protein or peptide is not MUC18.
-39. (canceled)
Dependencies are inferred from the claim text.